JAZZ — Jazz Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $13.92bn
- $16.07bn
- $4.27bn
Jazz Pharma to pay $145 million to settle narcolepsy drug antitrust case
U.S. STOCKS ON THE MOVE-Mobileye, Visionary Holdings, Wolfspeed
U.S. STOCKS ON THE MOVE-Energy firms, Jazz Pharma, KLX Energy
Jazz Pharma climbs after Morgan Stanley raises PT
Deals of the day-Mergers and acquisitions
Chimerix surges on Jazz Pharma's $935 million buyout
Deals of the day-Mergers and acquisitions
Brief: Jazz Pharmaceuticals Upon Termination Of Deal Chimerix Will Be Required To Pay Termination Fee Of $35 Million In Cash
Brief: Jazz Pharmaceuticals To Acquire Chimerix
Chimerix surges on Jazz Pharma's $935 million buyout
Jazz Pharmaceuticals to buy Chimerix for $935 million (updated)
Jazz Pharmaceuticals to buy Chimerix for $935 million
Jazz Pharmaceuticals PLC reports results for the quarter ended December 31 - Earnings Summary
Brief: Jazz Pharmaceuticals Q4 Adjusted EPS USD 6.6 Vs. IBES Estimate USD 5.81
Brief: Jazz Pharmaceuticals Expects To Meet 2024 Revenue Guidance
Brief: Jazz Pharmaceuticals Announces CEO Succession Plan
Brief: Jazz Pharmaceuticals Announces CEO Succession Plan
Brief: Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex® (Cannabidiol) Benefits
Brief: Jazz Pharmaceuticals Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include zanidatamab-hrii (Ziihera®)